All In Biotech

Drug Trial Radar · NCT04320342

A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD

A Phase III, 52-week, Multinational, Multicenter, Randomized, Double-blind, 2-arm Parallel Group Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide (CHF 5993) With the Fixed Dose Dual Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate (CHF 1535), Both Administered Via pMDI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,406 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,406

Actual

Start

Apr 27, 2022

Primary completion

Jan 12, 2026

Study completion Jan 12, 2026

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
Mar 25, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare CHF 5993 with CHF 1535 in improving lung function, reducing moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes in the target subject population.

Conditions

  • COPD
  • COPD Exacerbation

Interventions

  • Beclomethasone DipropionateDrug

    Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg

  • Glycopyrronium BromideDrug

    Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg

  • Formoterol FumarateDrug

    Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in pre-dose morning Forced Expiratory Volume in the 1st second (FEV1) at Week 28Time frame: Week 28

Locations

436 sites in 10 countries. Site status is shown where the registry gives one.

  • Chiesi Clinical Trial Site 840350

    Birmingham, Alabama

  • Chiesi Clinical Trial Site 840186

    Dothan, Alabama

  • Chiesi Clinical Trial Site 840258

    Foley, Alabama

  • Chiesi Clinical Trial Site 840279

    Jasper, Alabama

  • Chiesi Clinical Trial Site 840433

    Mobile, Alabama

  • Chiesi Clinical Trial Site 840206

    Montgomery, Alabama

  • Chiesi Clinical Trial Site 840249

    Muscle Shoals, Alabama

  • Chiesi Clinical Trial Site 840406

    Chandler, Arizona

  • Chiesi Clinical Trial Site 840402

    Peoria, Arizona

  • Chiesi Clinical Trial Site 840349

    Tucson, Arizona

  • Chiesi Clinical Trial Site 840404

    Covina, California

  • Chiesi Clinical Trial Site 840209

    Escondido, California

  • Chiesi Clinical Trial Site 840427

    La Palma, California

  • Chiesi Clinical Trial Site 840358

    Lomita, California

  • Chiesi Clinical Trial Site 840173

    Newport Beach, California

  • Chiesi Clinical Trial Site 840208

    Northridge, California

  • Chiesi Clinical Trial Site 840277

    Northridge, California

  • Chiesi Clinical Trial Site 840364

    Redding, California

  • Chiesi Clinical Trial Site 840226

    Sacramento, California

  • Chiesi Clinical Trial Site 840405

    Sacramento, California

  • Chiesi Clinical Trial Site 840107

    San Diego, California

  • Chiesi Clinical Trial Site 840373

    Santa Ana, California

  • Chiesi Clinical Trial Site 840164

    Upland, California

  • Chiesi Clinical Trial Site 840174

    West Covina, California

  • Chiesi Clinical Trial Site 840144

    Westminster, California

  • Chiesi Clinical Trial Site 840441

    Aurora, Colorado

  • Chiesi Clinical Trial Site 840229

    Boulder, Colorado

  • Chiesi Clinical Trial Site 840399

    Norwalk, Connecticut

  • Chiesi Clinical Trial Site 840116

    Altamonte Springs, Florida

  • Chiesi Clinical Trial Site 840268

    Aventura, Florida

  • Chiesi Clinical Trial Site 840192

    Brandon, Florida

  • Chiesi Clinical Trial Site 840310

    Brooksville, Florida

  • Chiesi Clinical Trial Site 840240

    Chiefland, Florida

  • Chiesi Clinical Trial Site 840153

    Clearwater, Florida

  • Chiesi Clinical Trial Site 840272

    Coral Gables, Florida

  • Chiesi Clinical Trial Site 840304

    Coral Gables, Florida

  • Chiesi Clinical Trial Site 840193

    Cutler Bay, Florida

  • Chiesi Clinical Trial Site 840311

    Cutler Bay, Florida

  • Chiesi Clinical Trial Site 840335

    Cutler Bay, Florida

  • Chiesi Clinical Trial Site 840141

    Daytona Beach, Florida

Showing 40 of 436 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.